<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(8)</volume><submitter>Kato K</submitter><pubmed_abstract>The recent increase in the number of molecular targeted agents for lung cancer has led to the demand for the simultaneous testing of multiple genes. Although gene panels using next-generation sequencing (NGS) are ideal, conventional panels require a high tumor content, and biopsy samples often do not meet this requirement. We developed a new NGS panel, called compact panel, characterized by high sensitivity, with detection limits for mutations of 0.14%, 0.20%, 0.48%, 0.24%, and 0.20% for &lt;i>EGFR&lt;/i> exon 19 deletion, L858R, T790M, &lt;i>BRAF&lt;/i> V600E, and &lt;i>KRAS&lt;/i> G12C, respectively. Mutation detection also had a high quantitative ability, with correlation coefficients ranging from 0.966 to 0.992. The threshold for fusion detection was 1%. The panel exhibited good concordance with the app</pubmed_abstract><journal>Diagnostics (Basel, Switzerland)</journal><pagination>1476</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10137435</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Analytical Performance of a Highly Sensitive System to Detect Gene Variants Using Next-Generation Sequencing for Lung Cancer Companion Diagnostics.</pubmed_title><pmcid>PMC10137435</pmcid><pubmed_authors>Kato K</pubmed_authors><pubmed_authors>Nakamura H</pubmed_authors><pubmed_authors>Okami J</pubmed_authors><pubmed_authors>Nakatsuka SI</pubmed_authors><pubmed_authors>Kukita Y</pubmed_authors><pubmed_authors>Higashiyama M</pubmed_authors><pubmed_authors>Honma K</pubmed_authors><pubmed_authors>Sato Y</pubmed_authors><pubmed_authors>Nakamura S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Analytical Performance of a Highly Sensitive System to Detect Gene Variants Using Next-Generation Sequencing for Lung Cancer Companion Diagnostics.</name><description>The recent increase in the number of molecular targeted agents for lung cancer has led to the demand for the simultaneous testing of multiple genes. Although gene panels using next-generation sequencing (NGS) are ideal, conventional panels require a high tumor content, and biopsy samples often do not meet this requirement. We developed a new NGS panel, called compact panel, characterized by high sensitivity, with detection limits for mutations of 0.14%, 0.20%, 0.48%, 0.24%, and 0.20% for &lt;i>EGFR&lt;/i> exon 19 deletion, L858R, T790M, &lt;i>BRAF&lt;/i> V600E, and &lt;i>KRAS&lt;/i> G12C, respectively. Mutation detection also had a high quantitative ability, with correlation coefficients ranging from 0.966 to 0.992. The threshold for fusion detection was 1%. The panel exhibited good concordance with the app</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Apr</publication><modification>2025-04-05T21:14:43.85Z</modification><creation>2025-04-05T21:14:43.85Z</creation></dates><accession>S-EPMC10137435</accession><cross_references><pubmed>37189577</pubmed><doi>10.3390/diagnostics13081476</doi></cross_references></HashMap>